scispace - formally typeset
K

Ka-Wing Cheng

Researcher at Shenzhen University

Publications -  121
Citations -  5565

Ka-Wing Cheng is an academic researcher from Shenzhen University. The author has contributed to research in topics: Chemistry & Medicine. The author has an hindex of 34, co-authored 103 publications receiving 4396 citations. Previous affiliations of Ka-Wing Cheng include The Chinese University of Hong Kong & Stony Brook University.

Papers
More filters
Journal ArticleDOI

Aerosol administration of phospho-sulindac inhibits lung tumorigenesis

TL;DR: It is found that administration by inhalation delivered high levels of phospho-sulindac to the lungs and minimized its hydrolysis to less active metabolites and was highly effective in inhibiting lung tumorigenesis and significantly improved the survival of mice bearing orthotopic A549 xenografts.
Journal ArticleDOI

Antibrowning activity of MRPs in enzyme and fresh-cut apple slice models.

TL;DR: The research indicates the limited application of MRPs as antibrowning agents for food products, and observation of an unpleasant odor from apple slices treated with MRPs raised another concern about the probable negative impact of these inhibitors on the sensory quality of food products.
Journal ArticleDOI

DHA protects against monosodium urate-induced inflammation through modulation of oxidative stress.

TL;DR: The results suggest that DHA or DHA-rich microalgal oil may be a promising natural agent for the prevention of MSU-induced inflammation and potentially acute gout at least partly by attenuating oxidative stress.
Journal ArticleDOI

Topical phospho-sulindac (OXT-328) is effective in the treatment of non-melanoma skin cancer

TL;DR: Topical P-S hydrogel is a promising treatment modality against non-melanoma skin cancer and merits further evaluation.
Journal ArticleDOI

Polysaccharide-Zein Composite Nanoparticles for Enhancing Cellular Uptake and Oral Bioavailability of Curcumin: Characterization, Anti-colorectal Cancer Effect, and Pharmacokinetics

TL;DR: HA-Zein-CUR has promising potential as an oral agent for the control of CRC and leads to enhanced delivery and accumulation of CUR in major organs/tissues, in particular CRC tumors and colon.